Treatments & Interventions
Pyridostigmine bromide
substance
Ambenonium chloride
substance
Neostigmine methylsulfate
substance
Pyridostigmine
substance
Neostigmine
substance
Ambenonium
substance
Neostigmine bromide
substance
Cyclophosphamide
substance
Cyclosporine
substance
Eculizumab
substance
Cyclophosphamide anhydrous
substance
Zilucoplan
substance
Clinical Trials
Recent Trials
Registry of Participants With Generalized Myasthenia Gravis Treated With Alexion C5 Inhibition Therapies (C5ITs)
A Worldwide Pregnancy Safety Study to Assess Maternal, Fetal, and Infant Outcomes Following Exposure to Efgartigimod During Pregnancy and/or Breastfeeding.
A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis
A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (RemeMG)
A Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Aged 18 to 85 Years With gMG.
Research Evidence
Peer-reviewed studies linked via MeSH term "Myasthenia Gravis" from the MEDLINE/PubMed database.
Research data from MEDLINE/PubMed
Signs & Symptoms
Based on Human Phenotype Ontology (HPO) disease-phenotype annotations.
Related Conditions
Quick Facts
- SNOMED CT
- 91637004
- UMLS CUI
- C0026896
- Fully Specified Name
- Myasthenia gravis (disorder)
- Specialists
- 0
- Diagnostic Biomarkers
- 0
- HPO Phenotypes
- 30
- Known Treatments
- 12
- Clinical Trials
- 19
This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.
Clinical content is derived from the SNOMED CT clinical ontology and curated medical knowledge graphs.